Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 3
2014 3
2015 3
2016 2
2017 2
2018 2
2019 2
2020 4
2021 5
2022 1
2023 4
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Update on the diagnosis of tuberculosis.
Kontsevaya I, Cabibbe AM, Cirillo DM, DiNardo AR, Frahm N, Gillespie SH, Holtzman D, Meiwes L, Petruccioli E, Reimann M, Ruhwald M, Sabiiti W, Saluzzo F, Tagliani E, Goletti D. Kontsevaya I, et al. Clin Microbiol Infect. 2024 Sep;30(9):1115-1122. doi: 10.1016/j.cmi.2023.07.014. Epub 2023 Jul 23. Clin Microbiol Infect. 2024. PMID: 37490968 Review.
Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.
Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M; UNITE4TB Consortium. Heyckendorf J, et al. Among authors: kontsevaya i. Clin Microbiol Rev. 2022 Sep 21;35(3):e0022721. doi: 10.1128/cmr.00227-21. Epub 2022 Mar 21. Clin Microbiol Rev. 2022. PMID: 35311552 Free PMC article. Review.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: kontsevaya i. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Free PMC article. Review.
Perspective for Precision Medicine for Tuberculosis.
Lange C, Aarnoutse R, Chesov D, van Crevel R, Gillespie SH, Grobbel HP, Kalsdorf B, Kontsevaya I, van Laarhoven A, Nishiguchi T, Mandalakas A, Merker M, Niemann S, Köhler N, Heyckendorf J, Reimann M, Ruhwald M, Sanchez-Carballo P, Schwudke D, Waldow F, DiNardo AR. Lange C, et al. Among authors: kontsevaya i. Front Immunol. 2020 Oct 8;11:566608. doi: 10.3389/fimmu.2020.566608. eCollection 2020. Front Immunol. 2020. PMID: 33117351 Free PMC article. Review.
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.
Gillespie SH, DiNardo AR, Georghiou SB, Sabiiti W, Kohli M, Panzner U, Kontsevaya I, Hittel N, Stuyver LJ, Tan JB, van Crevel R, Lange C, Thuong TNT, Heyckendorf J, Ruhwald M, Heinrich N. Gillespie SH, et al. Among authors: kontsevaya i. Lancet Microbe. 2024 Sep;5(9):100869. doi: 10.1016/S2666-5247(24)00085-5. Epub 2024 May 9. Lancet Microbe. 2024. PMID: 38735303 Free article. Review.
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. Diacon AH, et al. Among authors: kontsevaya i. Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365949 Free PMC article. Clinical Trial.
Perspectives for systems biology in the management of tuberculosis.
Kontsevaya I, Lange C, Comella-Del-Barrio P, Coarfa C, DiNardo AR, Gillespie SH, Hauptmann M, Leschczyk C, Mandalakas AM, Martinecz A, Merker M, Niemann S, Reimann M, Rzhepishevska O, Schaible UE, Scheu KM, Schurr E, Abel Zur Wiesch P, Heyckendorf J. Kontsevaya I, et al. Eur Respir Rev. 2021 May 25;30(160):200377. doi: 10.1183/16000617.0377-2020. Print 2021 Jun 30. Eur Respir Rev. 2021. PMID: 34039674 Free PMC article. Review.
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.
Lange C, Bothamley G, Günther G, Guglielmetti L, Kontsevaya I, Kuksa L, Lange B, Lorent N, Saluzzo F, Sester M, Tebruegge M, Tunesi S, Tweed C; Tuberculosis Network European Trials group (TBnet). Lange C, et al. Among authors: kontsevaya i. Pathog Immun. 2025 Mar 2;10(2):1-45. doi: 10.20411/pai.v10i2.791. eCollection 2025. Pathog Immun. 2025. PMID: 40062355 Free PMC article. Review.
Treatment for COVID-19-a cohort study from Northern Italy.
Guglielmetti L, Aschieri D, Kontsevaya I, Calabrese F, Donisi A, Faggi A, Ferrante P, Fronti E, Gerna L, Leoni MC, Paolillo F, Ratti G, Ruggieri A, Sacchini D, Scotti M, Valdatta C, Stabile M, Taliani G, Codeluppi M. Guglielmetti L, et al. Among authors: kontsevaya i. Sci Rep. 2021 Oct 25;11(1):20964. doi: 10.1038/s41598-021-00243-4. Sci Rep. 2021. PMID: 34697322 Free PMC article.
35 results